FI59596C - Foerfarande foer framstaellning av en terapeutiskt anvaendbar 7-(3-oxobutyl)-1,3-di-(n-butyl)xantin - Google Patents

Foerfarande foer framstaellning av en terapeutiskt anvaendbar 7-(3-oxobutyl)-1,3-di-(n-butyl)xantin Download PDF

Info

Publication number
FI59596C
FI59596C FI750122A FI750122A FI59596C FI 59596 C FI59596 C FI 59596C FI 750122 A FI750122 A FI 750122A FI 750122 A FI750122 A FI 750122A FI 59596 C FI59596 C FI 59596C
Authority
FI
Finland
Prior art keywords
butyl
oxobutyl
xanthine
therapeutic
effect
Prior art date
Application number
FI750122A
Other languages
English (en)
Finnish (fi)
Other versions
FI750122A (fr
FI59596B (fi
Inventor
Guenther Brenner
Joachim Goering
Eskendar Ali Kahn
Oskar Rohte
Manfred Tauscher
Original Assignee
Wuelfing J A Fa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2402908A external-priority patent/DE2402908C2/de
Application filed by Wuelfing J A Fa filed Critical Wuelfing J A Fa
Publication of FI750122A publication Critical patent/FI750122A/fi
Priority to FI801875A priority Critical patent/FI801875A/fi
Application granted granted Critical
Publication of FI59596B publication Critical patent/FI59596B/fi
Publication of FI59596C publication Critical patent/FI59596C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI750122A 1974-01-22 1975-01-20 Foerfarande foer framstaellning av en terapeutiskt anvaendbar 7-(3-oxobutyl)-1,3-di-(n-butyl)xantin FI59596C (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI801875A FI801875A (fi) 1974-01-22 1980-06-11 7-(oxoalkyl)-1,3-dialkylxantiner foerfarande foer deras framstaellning och laekemedel innehaollande dessa foereningar

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2402908A DE2402908C2 (de) 1974-01-22 1974-01-22 7-(3-Oxobutyl)-1,3-di-(n-butyl)-xanthin und Verfahren zu seiner Herstellung
DE2402908 1974-01-22

Publications (3)

Publication Number Publication Date
FI750122A FI750122A (fr) 1975-07-23
FI59596B FI59596B (fi) 1981-05-29
FI59596C true FI59596C (fi) 1981-09-10

Family

ID=5905372

Family Applications (1)

Application Number Title Priority Date Filing Date
FI750122A FI59596C (fi) 1974-01-22 1975-01-20 Foerfarande foer framstaellning av en terapeutiskt anvaendbar 7-(3-oxobutyl)-1,3-di-(n-butyl)xantin

Country Status (13)

Country Link
US (2) US4242345A (fr)
JP (1) JPS5912677B2 (fr)
AR (1) AR207462A1 (fr)
AT (1) AT338286B (fr)
BE (1) BE824665A (fr)
CA (1) CA1068693A (fr)
CH (1) CH608236A5 (fr)
FI (1) FI59596C (fr)
FR (1) FR2258183B1 (fr)
GB (1) GB1441562A (fr)
HU (1) HU169012B (fr)
NL (1) NL184330C (fr)
YU (1) YU15175A (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2507555A1 (de) * 1975-02-21 1976-09-02 Wuelfing J A Fa 7-(oxoalkyl)-1,3-dialkylxanthine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel
DE2507554A1 (de) * 1975-02-21 1976-09-02 Wuelfing J A Fa 7-(oxoalkyl)-1,3-dialkylxanthine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0005015B1 (fr) * 1978-04-22 1986-10-29 BEECHAM - WUELFING GmbH & Co. KG Utilisation d'un dérivé de xanthine dans la fabrication d'un médicament
IL59665A0 (en) * 1979-04-05 1980-06-30 Wuelfing J Kg Xanthine derivatives,process for their preparation and their use in pharmaceutical compositions
DE3173289D1 (en) * 1980-06-21 1986-02-06 Beecham Wuelfing Gmbh & Co Kg Xanthine derivatives, pharmaceutical compositions containing them and a process for their preparation
GB8418430D0 (en) * 1984-07-19 1984-08-22 Beecham Wuelfing Gmbh & Co Kg Treatment
JPS63225317A (ja) * 1986-10-06 1988-09-20 Hoechst Japan Kk 抗消化性潰瘍剤
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5096906A (en) * 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
JP2661666B2 (ja) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
US5321029A (en) * 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
CA2030112A1 (fr) * 1989-11-24 1991-05-25 Yasuo Ito Compose de xanthine, methode de preparation et composition pharmaceutique contenant ledit compose
EP0484785B1 (fr) * 1990-11-07 1996-05-22 Hoechst-Roussel Pharmaceuticals Incorporated Utilisation de xanthines pour la préparation de médicaments actifs comme inhibiteurs de la réplication des retrovirus humains
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
MX9203323A (es) * 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.
ATE146078T1 (de) * 1992-02-22 1996-12-15 Hoechst Ag Verwendung von xanthinderivaten zur behandlung von muskelschädigungen nach vollständiger unterbrechung der blutzirkulation
EP0570831A2 (fr) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Utilisation de dérivés de Xanthine pour le traitement de dommages cérébraux après interruption de la circulation sanguine
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
CA2460911C (fr) * 2001-10-01 2011-08-30 University Of Virginia Patent Foundation Analogues de 2-propynyle adenosine presentant une activite agoniste de a2a et compositions en contenant
US7442687B2 (en) * 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7605143B2 (en) * 2004-08-02 2009-10-20 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
WO2006028618A1 (fr) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation Analogues d'adenosine de propynyle 2-polycyclique presentant des groupes 5'-ribose modifies presentant une activite agoniste de a2a
WO2007120972A2 (fr) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Procede permettant de traiter l'anemie a hematies falciformes
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2761863A (en) * 1956-09-04 Lower-alkyl
US2756229A (en) * 1956-07-24 Xanthine derivatives
CA557342A (fr) 1958-05-13 Doebel Karl Procede de fabrication de nouveaux derives de xanthine
FR4791E (fr) 1900-06-29 1905-10-16 Eugene Fournier Lampe à pétrole perfectionnée pour chauffage intensif dite: "la naphteuse"
GB759174A (en) * 1952-11-07 1956-10-17 Geigy Ag J R Improvements in diuretic acting xanthine derivatives
DE926788C (de) 1952-11-07 1955-04-25 Geigy Ag J R Verfahren zur Herstellung von 1, 3-dialkylierten 7-Oxyalkyl-xanthinabkoemmlingen
GB759981A (en) * 1953-09-09 1956-10-24 Roche Products Ltd Process for the manufacture of xanthine derivatives
CH325292A (de) 1953-10-21 1957-10-31 Geigy Ag J R Verfahren zur Herstellung von 7-Oxyalkyl-xanthinderivaten
US3737433A (en) * 1964-09-05 1973-06-05 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines
DE2234202A1 (de) 1972-07-12 1974-01-24 Albert Ag Chem Werke Verfahren zur herstellung von oxoalkylxanthinen
DE2330742C2 (de) * 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2457666A1 (de) * 1974-12-06 1976-06-10 Hoechst Ag Arzneimittel, verfahren zur herstellung von dafuer geeigneten wirkstoffen und diese oxoalkyl-dialkyl-xanthine
JPS5233120A (en) * 1975-09-10 1977-03-14 Nisshin Steel Co Ltd Double coiled automobile steel pipe covered with heat flexible plastic resin

Also Published As

Publication number Publication date
AR207462A1 (es) 1976-10-08
NL7414887A (nl) 1975-07-24
US4291037A (en) 1981-09-22
FI750122A (fr) 1975-07-23
HU169012B (fr) 1976-08-28
US4242345A (en) 1980-12-30
NL184330B (nl) 1989-01-16
FR2258183B1 (fr) 1978-07-28
ATA929674A (de) 1976-12-15
GB1441562A (en) 1976-07-07
YU15175A (en) 1982-06-30
JPS5912677B2 (ja) 1984-03-24
AT338286B (de) 1977-08-10
BE824665A (fr) 1975-05-15
FR2258183A1 (fr) 1975-08-18
NL184330C (nl) 1989-06-16
FI59596B (fi) 1981-05-29
CH608236A5 (fr) 1978-12-29
JPS50101386A (fr) 1975-08-11
CA1068693A (fr) 1979-12-25

Similar Documents

Publication Publication Date Title
FI59596C (fi) Foerfarande foer framstaellning av en terapeutiskt anvaendbar 7-(3-oxobutyl)-1,3-di-(n-butyl)xantin
Hagelberg et al. Toxicokinetics of ochratoxin A in several species and its plasma‐binding properties
AU2023202704A1 (en) Compounds for positron emission tomography
PL136579B1 (en) Process for preparing derivatives of 2-propoxymethylguanine
JPS6146455B2 (fr)
CN101675927A (zh) 治疗分子及方法-1
JP2023517541A (ja) 不整脈の治療のためのニコチンアミドモノヌクレオチド誘導体
CA2454654A1 (fr) Composes pharmaceutiquement actifs a structure cyclique pyrazolotriazolopyrimidine tricyclique et procedes d'utilisation de ceux-ci
EP2542232A2 (fr) Inhibiteurs acides gras
KR900000370B1 (ko) 티아졸론 및 이의 제조방법
JP2865255B2 (ja) １，２，３，４，１０，１４ｂ‐ヘキサヒドロジベンゾ〔ｃ，ｆ〕ピラジノ〔１，２‐ａ〕アゼピノ誘導体及び１０‐アザ，１０‐オキサ及び１０‐チア類似体
Fisher et al. Influence of alkylating agents on kidney erythropoietin production
FI59250C (fi) Foerfarande foer framstaellning av cancerostatiskt och immunstimulerande verkande 4-imino-1,3-diazabicyklo-(3,1,0)-hexan-2-on
FI62089C (fi) Foerfarande foer framstaellning av pao det perifera blodomloppet verkande 7-(n-(3-fenoxi-2-hydroxipropyl)-n-amino)-1,3-dialkyl-xantinderivat
GB1570158A (en) Immunosuppressant substituted glutamine formulations
Mirskova et al. 2-Hydroxyethylammonium Salts of Organylsulphanyl (sylphonyl) acetic Acids as Novel Pharmacologically Active Compounds
Morikawa et al. 5-Isoquinolinesulfonamide derivatives. 2. Synthesis and vasodilatory activity of N-(2-aminoethyl)-5-isoquinoline sulfonamide derivatives
SU1347865A3 (ru) Способ получени производных триазолопиримидина или их солей с метансульфокислотой
CN107513055B (zh) 一种利巴韦林衍生化合物及其药物组合物
CN106038562A (zh) 一种治疗类风湿性关节炎的药物
Fisher et al. Cardiac output in horses
CN115477655B (zh) 与肿瘤坏死因子-α对接的二氧六环-四氢咔啉-3-甲酰氨基酸的制备和应用
CN1398183A (zh) 含铂络合物化合物的药物和其用途
PT90560B (pt) Processo para a preparacao de uma composicao farmaceutica contendo o derivado de tiazol acido 2-(3-carboxi-1-propiltio)-4-metil-1,3-tiazolil-5-acetico(tiprotimod) para terapia de infeccoes por virus
Mortimer The toxic effects of sporidesmin on mice

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: WUELFING, JOHANN A.